Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
  • Patent number: 10676500
    Abstract: The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): These compounds are useful as FXR or TGR5 modulators.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 9, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yong He, Brett Granger, Xuechao Xing, Yat Sun Or
  • Patent number: 10668123
    Abstract: Capsicum compositions are described that include biologically active constituents non-capsaicinoids and capsaicinoids in a specific ratio are useful for the treatment and management of cardiometabolic syndrome and associated risk factors, in a subject in need thereof. The capsicum compositions include a capsicum extract which is prepared by extracting capsicum pods by using suitable polar and non-polar solvents. Capsicum compositions include non-capsaicinoid components like saponins and polyphenols such as flavonoids, which along with capsaicinoids effectively reduce risk factors of cardiometabolic syndrome and also reduce oxidative stress on vital body organs by reducing inflammatory and/or oxidative markers. The capsicum compositions inhibit pancreatic lipase enzyme and enhance lipolysis, when administered in an effective amount to a subject in need thereof. Capsicum compositions as described herein are prepared by human intervention and are safe for consumption.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: June 2, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Vijaya Juturu, Khadija Ghanam, Vandita Srivastava, Jyotish Srivastava, Sudhakar Akella
  • Patent number: 10654834
    Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
  • Patent number: 10646499
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Patent number: 10576090
    Abstract: A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 3, 2020
    Assignee: Marius Pharmaceuticals LLC
    Inventor: Om Dhingra
  • Patent number: 10525065
    Abstract: Method and composition for treating psoriasis and other skin disorders.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 7, 2020
    Assignee: ANAPLASI PHARMACEUTICALS, LLC
    Inventor: Edward Richard Yuhas
  • Patent number: 10519192
    Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C.diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C.diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C.diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C.diff associated diseases and toxic megacolon.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: December 31, 2019
    Assignee: INSIGHT HEALTH LIMITED
    Inventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
  • Patent number: 10485809
    Abstract: Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.
    Type: Grant
    Filed: November 12, 2016
    Date of Patent: November 26, 2019
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Dong Wang, Fang Yuan, Zhenshan Jia, Xiaobei Wang
  • Patent number: 10478505
    Abstract: The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Michael A. Rogawski
  • Patent number: 10471086
    Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 12, 2019
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Salim Merali, Steven G. Kelsen, Carlos A. Barrero
  • Patent number: 10471064
    Abstract: The invention provides a pharmaceutical composition for treating atopic dermatitis of a human that is induced by Herpes simplex virus (HSV), said pharmaceutical composition comprising an effective amount of 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate and an effective amount of an Anti-allergic agent.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 12, 2019
    Inventor: Lily Hsiao
  • Patent number: 10441595
    Abstract: Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 15, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Chad S. Beus, Paul B. Savage
  • Patent number: 10434108
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 8, 2019
    Assignee: ALLERGAN SALES, LLC
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10434107
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 8, 2019
    Assignee: ALLERGAN SALES, LLC
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10421772
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 24, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 10407462
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 10, 2019
    Assignee: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • Patent number: 10369159
    Abstract: [Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor ?-inhibiting ? partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 6, 2019
    Assignees: Nobelpharma Co., Ltd., National University Corporation Tottori University
    Inventors: Kenichiro Nakao, Tasuku Harada, Fuminori Taniguchi
  • Patent number: 10369160
    Abstract: The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: August 6, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Antonio Moschetta, Jesus Maria Banales Asurmedi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, Oihane Erice Azparren
  • Patent number: 10344049
    Abstract: A compound and pharmaceutically acceptable salts thereof for treating cancer, having a structure represented by the following formula (I) or formula (II): in which X and Y each individually represent: R1, R2, R3, R4, and R5 individually represents hydrogen atom, acyl having 20 or less carbon atoms, alkyl having 20 or less carbon atoms, alkanoyl having 20 or less carbon atoms, aroyl having 20 or less carbon atoms, aryl having 20 or less carbon atoms, aralkyl having 20 or less carbon atoms, sulfonyl having 20 or less carbon atoms, phosphonyl having 20 or less carbon atoms, or haloacyl having 20 or less carbon atoms.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: July 9, 2019
    Assignee: AQUAVAN TECHNOLOGY CO., LTD
    Inventors: Shi-Yie Cheng, Yao-Ting Wang, Kuo-Tang Tseng, Wen-Hung Chen, Hsin Ju Wang
  • Patent number: 10278977
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Patent number: 10246481
    Abstract: Provided herein, inter alia, are methods for the preparation of modulators of farnesoid X receptor (FXR), and compositions and uses of the modulators of FXR.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 2, 2019
    Assignee: CITY OF HOPE
    Inventors: Donna Yu, Barry Forman
  • Patent number: 10238664
    Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Duke University
    Inventor: Eric J. Benner
  • Patent number: 10231982
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 19, 2019
    Assignee: Pop Test Oncology Limited Liability Company
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10202414
    Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkyl
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioello
  • Patent number: 10201550
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 12, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • Patent number: 10156564
    Abstract: Among the various aspects of the present disclosure is the provision of methods of detecting biomarkers of endoplasmic reticulum (ER) stress-associated kidney diseases. Another aspect of the present disclosure provides for a method of treating an endoplasmic reticulum (ER) stress-associated kidney disease in a subject.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 18, 2018
    Assignee: Washington University
    Inventors: Ying Chen, Yeawon Kim
  • Patent number: 10143721
    Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: December 4, 2018
    Assignees: The Population Council, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
  • Patent number: 10144759
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 4, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 10143938
    Abstract: The present application relates to a method for obtaining a mixture of estrogens from the pregnant mare's urine.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: December 4, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Chandrashaker Akula, John Lomans, Madhukiran Tummidi, Prashant Anil Tatake
  • Patent number: 10144757
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 4, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Patent number: 10064876
    Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 4, 2018
    Assignee: Vanderbilt University
    Inventors: Aurelio Galli, Heinrich J. G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
  • Patent number: 9987291
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 5, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9974866
    Abstract: The present invention provides polymer-polypeptide conjugates comprising a poly(2-oxazoline) amphiphilic block copolymer linked to a polypeptide and methods of use thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 22, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Alexander V. Kabanov, Jing Tong
  • Patent number: 9949986
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 24, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9895380
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Patent number: 9889101
    Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: February 13, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Paul F. Lambert, SangHyuk Chung
  • Patent number: 9867836
    Abstract: Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus).
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 16, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Chad S. Beus, Paul B. Savage
  • Patent number: 9770404
    Abstract: The present invention relates to a cosmetic composition for skin whitening and anti-aging, which contains 2 or more of collagen peptides, snake needle grass extract, and white ginseng saccharides as effective ingredients, improves skin resilience by increasing the content of collagen in the skin and suppresses the growth of melanin cells, improves skin brightness and uniformity, and alleviates skin yellowness and redness, so as to provide the effect of making the skin appear clearer and more radiant.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 26, 2017
    Assignee: Amorepacific Corporation
    Inventors: Kuan Chi Hsu, Hyeon Chung Kim, Sung II Park, Youn Joon Kim, Sang Hoon Han
  • Patent number: 9763964
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Patent number: 9758503
    Abstract: A compound with antitumor activities is represented by formula A or formula B R1, R2, R3, and R4 are independently hydrogen, hydroxyl, alkoxy, halogen, formyl, unsubstituted or substituted alkyl, or unsubstituted or substituted cycloalkyl.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: September 12, 2017
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Danni Tian, Minyi Jia, Xuechuan Wang, Xiaolin Xie, Dezhu Zhang
  • Patent number: 9700051
    Abstract: The present invention relates to the use of a compound chosen from squalamine and a squalamine-analog aminosteroid compound as agent for disinfecting an inert material object, in particular for the pre-disinfection of medical, dental, diagnostic or surgical equipment. The present invention also provides an aqueous or water-soluble disinfecting composition beneficial for a use according to the invention, characterized in that as disinfecting active compound it comprises a said antibacterial and antifungal compound selected from squalamine and a said squalamine-analog aminosteroid compound and suitable excipients for a water-soluble or aqueous formulation.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: July 11, 2017
    Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE, UNIVERSITE D'AIX MARSEILLE, FONDATION MEDITERRANEE INFECTION
    Inventors: Jean-Michel Brunel, Didier Raoult, Jean-Marc Rolain
  • Patent number: 9683008
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: June 20, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9670244
    Abstract: This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 6, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Farhad Parhami, Michael E. Jung, Jennifer R. Dwyer, Khanhlinh Nguyen
  • Patent number: 9650409
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 16, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 9636349
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9603858
    Abstract: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of a composition comprising a plant stanol and/or plant stanol ester. The present invention also relates to methods of improving the health status of a subject suffering from asthma and increasing the levels of IL-10 in a subject in need thereof.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: March 28, 2017
    Assignee: RAISIO NUTRITION LTD.
    Inventors: Florence Brull, Ronald P. Mensink, Jogehum Plat
  • Patent number: 9561199
    Abstract: The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 7, 2017
    Inventor: Alan B Cash
  • Patent number: 9540414
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari